Serevent is a drug owned by Glaxosmithkline Intellectual Property Ltd England. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 23, 2016. Details of Serevent's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5873360 (Pediatric) | Inhalation device |
Aug, 2016
(8 years ago) |
Expired
|
| US5873360 | Inhalation device |
Feb, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Serevent is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Serevent's family patents as well as insights into ongoing legal events on those patents.
Serevent's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Serevent's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 23, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Serevent Generics:
There are no approved generic versions for Serevent as of now.
Alternative Brands for Serevent
Serevent which is used for various medical conditions., has several other brand drugs using the same active ingredient (Salmeterol Xinafoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| Glaxo Grp Ltd |
| ||||
| Teva Pharm |
|
About Serevent
Serevent is a drug owned by Glaxosmithkline Intellectual Property Ltd England. It is used for various medical conditions. Serevent uses Salmeterol Xinafoate as an active ingredient. Serevent was launched by Glaxosmithkline in 1997.
Approval Date:
Serevent was approved by FDA for market use on 19 September, 1997.
Active Ingredient:
Serevent uses Salmeterol Xinafoate as the active ingredient. Check out other Drugs and Companies using Salmeterol Xinafoate ingredient
Treatment:
Serevent is used for various medical conditions.
Dosage:
Serevent is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.05MG BASE/INH | POWDER | Prescription | INHALATION |